| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunosuppressive Agents | 133 | 2024 | 838 | 11.480 |
Why?
|
| Sirolimus | 60 | 2025 | 282 | 6.580 |
Why?
|
| Cyclosporine | 74 | 2019 | 256 | 6.150 |
Why?
|
| Tandem Mass Spectrometry | 41 | 2026 | 572 | 5.460 |
Why?
|
| Tacrolimus | 47 | 2025 | 196 | 4.350 |
Why?
|
| Chromatography, High Pressure Liquid | 69 | 2026 | 592 | 4.310 |
Why?
|
| Kidney Transplantation | 47 | 2025 | 712 | 3.520 |
Why?
|
| Drug Monitoring | 23 | 2020 | 401 | 3.000 |
Why?
|
| Metabolomics | 19 | 2025 | 733 | 2.720 |
Why?
|
| Chromatography, Liquid | 27 | 2026 | 450 | 2.480 |
Why?
|
| Mycophenolic Acid | 15 | 2017 | 119 | 2.250 |
Why?
|
| Kidney | 25 | 2022 | 1497 | 2.100 |
Why?
|
| Microsomes, Liver | 19 | 2019 | 85 | 1.980 |
Why?
|
| Everolimus | 25 | 2020 | 112 | 1.900 |
Why?
|
| Mass Spectrometry | 34 | 2021 | 732 | 1.750 |
Why?
|
| Cannabinoids | 12 | 2026 | 184 | 1.740 |
Why?
|
| Dronabinol | 17 | 2026 | 249 | 1.700 |
Why?
|
| Biomarkers | 29 | 2025 | 4302 | 1.690 |
Why?
|
| Graft Rejection | 26 | 2019 | 521 | 1.340 |
Why?
|
| Liver Transplantation | 28 | 2018 | 827 | 1.290 |
Why?
|
| Substance Abuse Detection | 5 | 2026 | 110 | 1.270 |
Why?
|
| Proteomics | 18 | 2024 | 1188 | 1.200 |
Why?
|
| Cannabidiol | 7 | 2025 | 142 | 1.110 |
Why?
|
| Plant Extracts | 6 | 2024 | 188 | 1.080 |
Why?
|
| Cannabis | 12 | 2024 | 510 | 1.050 |
Why?
|
| Cyclophilins | 2 | 2017 | 40 | 1.010 |
Why?
|
| Humans | 247 | 2026 | 145783 | 1.010 |
Why?
|
| Rats | 63 | 2026 | 5585 | 1.010 |
Why?
|
| Oxidative Stress | 17 | 2019 | 1360 | 0.990 |
Why?
|
| Metabolome | 6 | 2025 | 391 | 0.990 |
Why?
|
| Cytochrome P-450 CYP3A | 20 | 2021 | 93 | 0.990 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 440 | 0.960 |
Why?
|
| Organ Transplantation | 10 | 2019 | 253 | 0.960 |
Why?
|
| Hallucinogens | 6 | 2024 | 111 | 0.950 |
Why?
|
| Xylazine | 1 | 2026 | 16 | 0.930 |
Why?
|
| Pravastatin | 9 | 2021 | 45 | 0.920 |
Why?
|
| Dried Blood Spot Testing | 3 | 2020 | 126 | 0.920 |
Why?
|
| Hydrocortisone | 3 | 2025 | 298 | 0.900 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 8 | 2019 | 174 | 0.890 |
Why?
|
| Drug Interactions | 27 | 2025 | 405 | 0.890 |
Why?
|
| Reproducibility of Results | 27 | 2025 | 3418 | 0.870 |
Why?
|
| Immunoassay | 3 | 2020 | 109 | 0.860 |
Why?
|
| Allografts | 1 | 2025 | 152 | 0.850 |
Why?
|
| Cytochrome P-450 Enzyme System | 17 | 2019 | 162 | 0.850 |
Why?
|
| Animals | 123 | 2026 | 38102 | 0.820 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 235 | 0.800 |
Why?
|
| Male | 147 | 2026 | 73011 | 0.780 |
Why?
|
| Proteome | 5 | 2017 | 513 | 0.770 |
Why?
|
| Kidney Failure, Chronic | 5 | 2025 | 599 | 0.760 |
Why?
|
| Mitochondria | 6 | 2017 | 993 | 0.760 |
Why?
|
| Lovastatin | 7 | 2013 | 37 | 0.750 |
Why?
|
| Drugs, Generic | 4 | 2019 | 28 | 0.750 |
Why?
|
| Female | 123 | 2026 | 79045 | 0.750 |
Why?
|
| Factor Xa Inhibitors | 2 | 2025 | 194 | 0.740 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2015 | 444 | 0.730 |
Why?
|
| Nucleotides | 2 | 2017 | 129 | 0.720 |
Why?
|
| Pharmaceutical Preparations | 3 | 2017 | 171 | 0.700 |
Why?
|
| Isoprostanes | 4 | 2012 | 15 | 0.700 |
Why?
|
| Intestinal Mucosa | 7 | 2017 | 675 | 0.700 |
Why?
|
| Magnetic Resonance Spectroscopy | 18 | 2017 | 627 | 0.690 |
Why?
|
| United States Food and Drug Administration | 3 | 2020 | 208 | 0.690 |
Why?
|
| Biological Availability | 12 | 2019 | 145 | 0.690 |
Why?
|
| Cortisone | 1 | 2021 | 16 | 0.690 |
Why?
|
| Adaptation, Physiological | 2 | 2025 | 560 | 0.690 |
Why?
|
| Dose-Response Relationship, Drug | 27 | 2026 | 2028 | 0.690 |
Why?
|
| Pregnanolone | 1 | 2021 | 34 | 0.660 |
Why?
|
| Cyclosporins | 18 | 2001 | 71 | 0.650 |
Why?
|
| Endocannabinoids | 5 | 2025 | 56 | 0.650 |
Why?
|
| TOR Serine-Threonine Kinases | 7 | 2016 | 456 | 0.650 |
Why?
|
| Urine | 2 | 2017 | 64 | 0.640 |
Why?
|
| Transplant Recipients | 4 | 2019 | 182 | 0.640 |
Why?
|
| Estrogen Receptor beta | 2 | 2012 | 40 | 0.630 |
Why?
|
| Drug-Eluting Stents | 7 | 2025 | 88 | 0.630 |
Why?
|
| Energy Metabolism | 17 | 2022 | 935 | 0.620 |
Why?
|
| Dinoprost | 6 | 2019 | 51 | 0.620 |
Why?
|
| Progesterone | 1 | 2021 | 215 | 0.610 |
Why?
|
| Therapeutic Equivalency | 6 | 2019 | 31 | 0.600 |
Why?
|
| Limit of Detection | 11 | 2024 | 92 | 0.590 |
Why?
|
| Pharmacology | 1 | 2019 | 10 | 0.590 |
Why?
|
| Substance-Related Disorders | 2 | 2026 | 1103 | 0.580 |
Why?
|
| Hemorrhage | 2 | 2025 | 822 | 0.580 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 6 | 2004 | 45 | 0.580 |
Why?
|
| Tissue Distribution | 12 | 2019 | 335 | 0.570 |
Why?
|
| Brain | 14 | 2026 | 2969 | 0.560 |
Why?
|
| Signal Transduction | 11 | 2017 | 5224 | 0.550 |
Why?
|
| Models, Biological | 9 | 2021 | 1764 | 0.550 |
Why?
|
| Analgesics, Opioid | 9 | 2025 | 1154 | 0.550 |
Why?
|
| Therapies, Investigational | 1 | 2017 | 19 | 0.520 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.520 |
Why?
|
| Intestine, Small | 5 | 2006 | 167 | 0.510 |
Why?
|
| Rats, Wistar | 16 | 2024 | 450 | 0.510 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.510 |
Why?
|
| Cardiovascular Agents | 5 | 2025 | 166 | 0.500 |
Why?
|
| Toxicity Tests | 1 | 2017 | 53 | 0.500 |
Why?
|
| Menopause | 3 | 2019 | 326 | 0.500 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2024 | 655 | 0.500 |
Why?
|
| Administration, Oral | 15 | 2026 | 867 | 0.500 |
Why?
|
| Myocardium | 4 | 2017 | 935 | 0.480 |
Why?
|
| Anisakis | 1 | 2016 | 2 | 0.470 |
Why?
|
| Helminth Proteins | 1 | 2016 | 24 | 0.470 |
Why?
|
| Anticoagulants | 2 | 2020 | 748 | 0.460 |
Why?
|
| Choline | 3 | 2022 | 138 | 0.460 |
Why?
|
| Marijuana Smoking | 4 | 2025 | 249 | 0.460 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 529 | 0.450 |
Why?
|
| Kidney Diseases | 3 | 2018 | 426 | 0.450 |
Why?
|
| Fishes | 1 | 2016 | 110 | 0.450 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 308 | 0.440 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 96 | 0.440 |
Why?
|
| Oxidoreductases, N-Demethylating | 6 | 2004 | 17 | 0.430 |
Why?
|
| Adult | 65 | 2026 | 40881 | 0.430 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 204 | 0.420 |
Why?
|
| Sensitivity and Specificity | 12 | 2024 | 2000 | 0.420 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2024 | 40 | 0.410 |
Why?
|
| Amino Acids | 3 | 2016 | 519 | 0.400 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 172 | 0.400 |
Why?
|
| Polyenes | 8 | 1998 | 17 | 0.400 |
Why?
|
| Premature Birth | 3 | 2025 | 390 | 0.400 |
Why?
|
| Hydroxyurea | 1 | 2013 | 34 | 0.390 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2013 | 34 | 0.390 |
Why?
|
| Molecular Structure | 10 | 2014 | 487 | 0.390 |
Why?
|
| Metabolic Clearance Rate | 9 | 2019 | 115 | 0.390 |
Why?
|
| Protein Kinases | 4 | 2017 | 312 | 0.390 |
Why?
|
| Anticholesteremic Agents | 4 | 2007 | 155 | 0.390 |
Why?
|
| Liver | 15 | 2026 | 1899 | 0.390 |
Why?
|
| Piperazines | 4 | 2009 | 375 | 0.380 |
Why?
|
| Coated Materials, Biocompatible | 3 | 2020 | 65 | 0.370 |
Why?
|
| Cerebrospinal Fluid | 1 | 2013 | 88 | 0.370 |
Why?
|
| Transplantation, Homologous | 9 | 2025 | 419 | 0.370 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.370 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2021 | 849 | 0.360 |
Why?
|
| Drug Therapy, Combination | 18 | 2025 | 1043 | 0.360 |
Why?
|
| Pyrimidines | 4 | 2014 | 530 | 0.360 |
Why?
|
| In Vitro Techniques | 18 | 2017 | 1049 | 0.360 |
Why?
|
| Middle Aged | 50 | 2025 | 36309 | 0.360 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2012 | 34 | 0.360 |
Why?
|
| Heart Transplantation | 8 | 2017 | 680 | 0.360 |
Why?
|
| Vasomotor System | 1 | 2012 | 47 | 0.360 |
Why?
|
| Macrophages, Alveolar | 4 | 2016 | 373 | 0.340 |
Why?
|
| Antineoplastic Agents | 7 | 2020 | 2219 | 0.340 |
Why?
|
| Double-Blind Method | 12 | 2026 | 2064 | 0.340 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2026 | 2525 | 0.340 |
Why?
|
| Hypoxia | 6 | 2024 | 1199 | 0.340 |
Why?
|
| Young Adult | 26 | 2026 | 14254 | 0.330 |
Why?
|
| Prospective Studies | 19 | 2025 | 8078 | 0.330 |
Why?
|
| Adolescent | 31 | 2025 | 22577 | 0.330 |
Why?
|
| Area Under Curve | 9 | 2021 | 332 | 0.330 |
Why?
|
| Lung Transplantation | 8 | 2000 | 332 | 0.330 |
Why?
|
| Neonatal Abstinence Syndrome | 2 | 2021 | 27 | 0.330 |
Why?
|
| Microsomes | 5 | 1998 | 33 | 0.320 |
Why?
|
| Swine | 15 | 2017 | 826 | 0.320 |
Why?
|
| Child | 26 | 2025 | 22740 | 0.320 |
Why?
|
| Artifacts | 1 | 2011 | 143 | 0.320 |
Why?
|
| Disease Models, Animal | 13 | 2026 | 4568 | 0.310 |
Why?
|
| Acetaminophen | 1 | 2013 | 267 | 0.310 |
Why?
|
| Hydroxylation | 5 | 2019 | 47 | 0.310 |
Why?
|
| Graft Survival | 6 | 2018 | 519 | 0.300 |
Why?
|
| Calcineurin Inhibitors | 6 | 2014 | 69 | 0.300 |
Why?
|
| Phosphates | 5 | 2012 | 177 | 0.300 |
Why?
|
| Drug Approval | 1 | 2010 | 93 | 0.300 |
Why?
|
| Cell Proliferation | 10 | 2020 | 2514 | 0.290 |
Why?
|
| Bile | 7 | 1992 | 26 | 0.290 |
Why?
|
| Isoniazid | 2 | 2006 | 70 | 0.290 |
Why?
|
| Lidocaine | 2 | 2023 | 55 | 0.290 |
Why?
|
| Theophylline | 2 | 2020 | 41 | 0.290 |
Why?
|
| Endothelium, Vascular | 4 | 2019 | 956 | 0.290 |
Why?
|
| Diltiazem | 3 | 1997 | 17 | 0.280 |
Why?
|
| Glucose | 7 | 2017 | 1049 | 0.280 |
Why?
|
| Time Factors | 19 | 2025 | 7134 | 0.280 |
Why?
|
| Flavanones | 1 | 2008 | 6 | 0.280 |
Why?
|
| Medical Marijuana | 2 | 2021 | 122 | 0.280 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2008 | 24 | 0.280 |
Why?
|
| Paclitaxel | 3 | 2020 | 259 | 0.280 |
Why?
|
| Cross-Over Studies | 6 | 2025 | 610 | 0.270 |
Why?
|
| HIV Protease Inhibitors | 3 | 2019 | 69 | 0.270 |
Why?
|
| Pregnancy | 13 | 2025 | 7216 | 0.270 |
Why?
|
| Child, Preschool | 13 | 2025 | 11868 | 0.270 |
Why?
|
| Neurons | 3 | 2019 | 1652 | 0.270 |
Why?
|
| Liver Function Tests | 5 | 2025 | 105 | 0.270 |
Why?
|
| Biotransformation | 18 | 2021 | 62 | 0.260 |
Why?
|
| Calcium Channel Blockers | 3 | 1997 | 166 | 0.260 |
Why?
|
| Mice | 21 | 2026 | 18356 | 0.260 |
Why?
|
| Mice, Knockout | 7 | 2026 | 3130 | 0.260 |
Why?
|
| Buprenorphine | 2 | 2021 | 192 | 0.260 |
Why?
|
| Angioplasty, Balloon | 3 | 2020 | 94 | 0.250 |
Why?
|
| Naltrexone | 1 | 2008 | 115 | 0.250 |
Why?
|
| Drug Stability | 4 | 2013 | 169 | 0.250 |
Why?
|
| Pyridostigmine Bromide | 1 | 2006 | 5 | 0.250 |
Why?
|
| Lipase | 2 | 2020 | 75 | 0.250 |
Why?
|
| Half-Life | 8 | 2019 | 155 | 0.240 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2006 | 41 | 0.240 |
Why?
|
| Tachycardia | 1 | 2006 | 58 | 0.240 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 47 | 0.240 |
Why?
|
| Coronary Artery Disease | 3 | 2025 | 750 | 0.240 |
Why?
|
| Glomerular Filtration Rate | 8 | 2022 | 765 | 0.240 |
Why?
|
| Reactive Oxygen Species | 4 | 2010 | 611 | 0.240 |
Why?
|
| Macaca fascicularis | 13 | 2008 | 70 | 0.230 |
Why?
|
| Regression Analysis | 5 | 2020 | 1001 | 0.230 |
Why?
|
| Cannabinoid Receptor Agonists | 5 | 2024 | 44 | 0.230 |
Why?
|
| Drug Carriers | 2 | 2020 | 136 | 0.230 |
Why?
|
| Postoperative Complications | 6 | 2025 | 2977 | 0.230 |
Why?
|
| Iodide Peroxidase | 1 | 2026 | 35 | 0.230 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 297 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 6 | 2025 | 1925 | 0.230 |
Why?
|
| Dogs | 6 | 2025 | 478 | 0.230 |
Why?
|
| Pipecolic Acids | 1 | 2025 | 26 | 0.230 |
Why?
|
| Coronary Thrombosis | 1 | 2025 | 25 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 11 | 2026 | 5993 | 0.230 |
Why?
|
| Abdominal Neoplasms | 1 | 2025 | 47 | 0.230 |
Why?
|
| Drug Delivery Systems | 4 | 2020 | 381 | 0.220 |
Why?
|
| Isomerism | 2 | 2024 | 56 | 0.220 |
Why?
|
| Corticosterone | 2 | 2024 | 241 | 0.220 |
Why?
|
| Heptanoic Acids | 2 | 2007 | 67 | 0.220 |
Why?
|
| Cell Line, Tumor | 8 | 2017 | 3551 | 0.220 |
Why?
|
| Hyperglycinemia, Nonketotic | 1 | 2026 | 56 | 0.220 |
Why?
|
| Depression | 3 | 2025 | 1559 | 0.220 |
Why?
|
| Catheters | 2 | 2017 | 74 | 0.220 |
Why?
|
| Drug Synergism | 7 | 2014 | 354 | 0.220 |
Why?
|
| Caffeine | 1 | 2025 | 74 | 0.220 |
Why?
|
| Cell-Derived Microparticles | 2 | 2018 | 73 | 0.220 |
Why?
|
| Serine | 1 | 2026 | 143 | 0.220 |
Why?
|
| Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.220 |
Why?
|
| Cholic Acid | 1 | 2024 | 4 | 0.220 |
Why?
|
| Epilepsy | 2 | 2020 | 390 | 0.220 |
Why?
|
| Alkaloids | 1 | 2024 | 28 | 0.220 |
Why?
|
| Oxylipins | 1 | 2025 | 47 | 0.220 |
Why?
|
| Mitragyna | 1 | 2024 | 8 | 0.210 |
Why?
|
| Attention | 2 | 2026 | 463 | 0.210 |
Why?
|
| Clemastine | 1 | 2024 | 1 | 0.210 |
Why?
|
| Glycine | 1 | 2026 | 186 | 0.210 |
Why?
|
| Wound Infection | 1 | 2025 | 60 | 0.210 |
Why?
|
| Enzyme Inhibitors | 4 | 2012 | 821 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2019 | 440 | 0.210 |
Why?
|
| Inflammation | 9 | 2025 | 2884 | 0.210 |
Why?
|
| Infant, Newborn | 12 | 2024 | 6465 | 0.210 |
Why?
|
| Ketorolac | 2 | 2017 | 33 | 0.210 |
Why?
|
| Benzylidene Compounds | 2 | 2017 | 20 | 0.210 |
Why?
|
| Diphosphonates | 1 | 2025 | 68 | 0.210 |
Why?
|
| Bezafibrate | 1 | 2024 | 10 | 0.210 |
Why?
|
| Acyl-CoA Dehydrogenases | 1 | 2024 | 12 | 0.210 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2004 | 87 | 0.210 |
Why?
|
| Folic Acid | 1 | 2026 | 198 | 0.210 |
Why?
|
| Cholesterol | 5 | 2013 | 408 | 0.210 |
Why?
|
| Pyridinium Compounds | 1 | 2024 | 31 | 0.210 |
Why?
|
| Kinetics | 8 | 2013 | 1568 | 0.210 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1777 | 0.210 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2025 | 134 | 0.210 |
Why?
|
| Pyrroles | 2 | 2007 | 220 | 0.210 |
Why?
|
| Animals, Newborn | 3 | 2024 | 896 | 0.200 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 102 | 0.200 |
Why?
|
| Cell Line | 7 | 2017 | 2823 | 0.200 |
Why?
|
| Birth Weight | 2 | 2024 | 517 | 0.200 |
Why?
|
| Glycerides | 1 | 2024 | 16 | 0.200 |
Why?
|
| Acidosis, Lactic | 1 | 2024 | 46 | 0.200 |
Why?
|
| Morphine | 2 | 2018 | 169 | 0.200 |
Why?
|
| Arachidonic Acids | 1 | 2024 | 42 | 0.200 |
Why?
|
| Gestational Age | 3 | 2022 | 990 | 0.200 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 238 | 0.200 |
Why?
|
| Central Nervous System Stimulants | 1 | 2025 | 185 | 0.200 |
Why?
|
| Myocardial Infarction | 3 | 2026 | 1211 | 0.200 |
Why?
|
| Deoxycytidine | 1 | 2025 | 220 | 0.200 |
Why?
|
| Leukemia | 2 | 2020 | 246 | 0.200 |
Why?
|
| Macrolides | 1 | 2003 | 67 | 0.190 |
Why?
|
| Niacinamide | 1 | 2024 | 104 | 0.190 |
Why?
|
| Mixed Function Oxygenases | 5 | 2001 | 43 | 0.190 |
Why?
|
| Rivaroxaban | 1 | 2025 | 271 | 0.190 |
Why?
|
| Adiponectin | 1 | 2025 | 242 | 0.190 |
Why?
|
| Transplantation | 4 | 2016 | 33 | 0.190 |
Why?
|
| Anti-HIV Agents | 3 | 2013 | 912 | 0.190 |
Why?
|
| Analgesia | 1 | 2024 | 106 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 2 | 2015 | 57 | 0.190 |
Why?
|
| Glycolysis | 4 | 2012 | 340 | 0.190 |
Why?
|
| Psychomotor Performance | 1 | 2025 | 324 | 0.180 |
Why?
|
| Blotting, Western | 8 | 2012 | 1184 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2005 | 256 | 0.180 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 605 | 0.180 |
Why?
|
| Rats, Inbred Lew | 11 | 2012 | 105 | 0.180 |
Why?
|
| White Matter | 1 | 2024 | 155 | 0.180 |
Why?
|
| Glutamine | 3 | 2012 | 109 | 0.180 |
Why?
|
| Pharmacogenetics | 3 | 2010 | 175 | 0.180 |
Why?
|
| Blood Transfusion | 1 | 2025 | 409 | 0.180 |
Why?
|
| Fetal Growth Retardation | 2 | 2018 | 593 | 0.180 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2022 | 118 | 0.180 |
Why?
|
| Aminophylline | 2 | 2020 | 12 | 0.170 |
Why?
|
| Homocysteine | 2 | 2019 | 152 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2021 | 484 | 0.170 |
Why?
|
| Heart Rate, Fetal | 1 | 2021 | 31 | 0.170 |
Why?
|
| TRPP Cation Channels | 1 | 2022 | 74 | 0.170 |
Why?
|
| Kynurenine | 2 | 2022 | 114 | 0.170 |
Why?
|
| Prostaglandins | 2 | 2019 | 94 | 0.170 |
Why?
|
| Biological Transport, Active | 5 | 2006 | 69 | 0.170 |
Why?
|
| Transplantation, Heterologous | 3 | 2006 | 170 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 185 | 0.170 |
Why?
|
| Arginine | 2 | 2025 | 264 | 0.170 |
Why?
|
| Fetal Development | 2 | 2021 | 298 | 0.170 |
Why?
|
| Aged | 19 | 2025 | 26217 | 0.170 |
Why?
|
| Myocytes, Cardiac | 1 | 2026 | 546 | 0.170 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 128 | 0.160 |
Why?
|
| Hepatectomy | 2 | 2023 | 274 | 0.160 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 5 | 2012 | 110 | 0.160 |
Why?
|
| Hypoxia-Ischemia, Brain | 2 | 2020 | 50 | 0.160 |
Why?
|
| Pilot Projects | 8 | 2023 | 1898 | 0.160 |
Why?
|
| Pain | 2 | 2025 | 791 | 0.160 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2018 | 194 | 0.160 |
Why?
|
| Marijuana Abuse | 1 | 2023 | 214 | 0.160 |
Why?
|
| Anesthetics, Intravenous | 2 | 2016 | 69 | 0.160 |
Why?
|
| Avoidance Learning | 2 | 2024 | 63 | 0.160 |
Why?
|
| Hypothalamus | 2 | 2018 | 163 | 0.160 |
Why?
|
| Organic Anion Transporters | 2 | 2011 | 13 | 0.160 |
Why?
|
| Microspheres | 2 | 2020 | 142 | 0.160 |
Why?
|
| Complement Pathway, Alternative | 2 | 2018 | 121 | 0.160 |
Why?
|
| Coronary Restenosis | 2 | 2010 | 22 | 0.160 |
Why?
|
| Cardiomyopathies | 1 | 2024 | 335 | 0.160 |
Why?
|
| Keratosis | 1 | 2020 | 16 | 0.160 |
Why?
|
| Glutamic Acid | 2 | 2018 | 255 | 0.160 |
Why?
|
| Lactones | 1 | 2000 | 59 | 0.160 |
Why?
|
| Heart Defects, Congenital | 2 | 2018 | 910 | 0.160 |
Why?
|
| Infusions, Intravenous | 4 | 2018 | 428 | 0.160 |
Why?
|
| Losartan | 1 | 2000 | 13 | 0.160 |
Why?
|
| Infant | 11 | 2024 | 10091 | 0.150 |
Why?
|
| Complement Activation | 3 | 2018 | 399 | 0.150 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.150 |
Why?
|
| Treatment Outcome | 12 | 2025 | 11794 | 0.150 |
Why?
|
| Volatilization | 1 | 2019 | 45 | 0.150 |
Why?
|
| Pyridines | 2 | 2017 | 609 | 0.150 |
Why?
|
| Tetrazoles | 1 | 2000 | 50 | 0.150 |
Why?
|
| Amygdala | 3 | 2024 | 200 | 0.150 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 112 | 0.150 |
Why?
|
| Reference Standards | 5 | 2016 | 177 | 0.150 |
Why?
|
| Carotid Arteries | 2 | 2018 | 208 | 0.150 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.150 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2025 | 549 | 0.150 |
Why?
|
| Brain Chemistry | 1 | 2000 | 120 | 0.150 |
Why?
|
| Adenosine | 4 | 2017 | 255 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2026 | 17330 | 0.150 |
Why?
|
| Angiotensin II | 1 | 2000 | 102 | 0.150 |
Why?
|
| Age Factors | 7 | 2018 | 3346 | 0.150 |
Why?
|
| Milk, Human | 1 | 2021 | 175 | 0.150 |
Why?
|
| Case-Control Studies | 7 | 2025 | 3634 | 0.150 |
Why?
|
| Astrocytes | 4 | 2011 | 228 | 0.150 |
Why?
|
| Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
|
| Hypothermia, Induced | 1 | 2020 | 96 | 0.150 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 85 | 0.150 |
Why?
|
| Leukotrienes | 1 | 2019 | 28 | 0.150 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 2 | 2017 | 94 | 0.150 |
Why?
|
| Spine | 1 | 2021 | 182 | 0.140 |
Why?
|
| Mental Disorders | 2 | 2021 | 1171 | 0.140 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2000 | 144 | 0.140 |
Why?
|
| Opiate Substitution Treatment | 1 | 2021 | 189 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 2393 | 0.140 |
Why?
|
| Perfusion | 6 | 2017 | 251 | 0.140 |
Why?
|
| Vascular Diseases | 2 | 2019 | 252 | 0.140 |
Why?
|
| Fentanyl | 2 | 2011 | 128 | 0.140 |
Why?
|
| Taurine | 1 | 2019 | 41 | 0.140 |
Why?
|
| Bilirubin | 3 | 1995 | 99 | 0.140 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2019 | 65 | 0.140 |
Why?
|
| Coronary Care Units | 1 | 2018 | 27 | 0.140 |
Why?
|
| Caspase 3 | 2 | 2017 | 242 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 175 | 0.140 |
Why?
|
| Imidazoles | 1 | 2000 | 247 | 0.140 |
Why?
|
| Legislation, Drug | 1 | 1999 | 73 | 0.140 |
Why?
|
| Atmospheric Pressure | 3 | 2021 | 26 | 0.140 |
Why?
|
| Homocystinuria | 1 | 2019 | 62 | 0.140 |
Why?
|
| Systems Biology | 1 | 2019 | 68 | 0.140 |
Why?
|
| Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
|
| Naphthalenes | 1 | 1998 | 54 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 334 | 0.140 |
Why?
|
| Phosphocreatine | 3 | 2004 | 44 | 0.140 |
Why?
|
| Creatinine | 5 | 2022 | 515 | 0.140 |
Why?
|
| Iohexol | 1 | 2018 | 23 | 0.140 |
Why?
|
| Methadone | 1 | 2020 | 123 | 0.140 |
Why?
|
| Reference Values | 4 | 2013 | 798 | 0.130 |
Why?
|
| Enzyme Activation | 2 | 2017 | 762 | 0.130 |
Why?
|
| DNA Damage | 2 | 2019 | 437 | 0.130 |
Why?
|
| Excipients | 1 | 2018 | 55 | 0.130 |
Why?
|
| Phospholipids | 5 | 2013 | 214 | 0.130 |
Why?
|
| Genotype | 5 | 2019 | 1857 | 0.130 |
Why?
|
| Lysophosphatidylcholines | 1 | 2017 | 23 | 0.130 |
Why?
|
| Anticonvulsants | 1 | 2020 | 246 | 0.130 |
Why?
|
| Diet, Ketogenic | 1 | 2018 | 39 | 0.130 |
Why?
|
| Vascular Access Devices | 1 | 2018 | 30 | 0.130 |
Why?
|
| Glucuronides | 2 | 2022 | 18 | 0.130 |
Why?
|
| Phenylpropionates | 1 | 2017 | 27 | 0.130 |
Why?
|
| Cysteine | 1 | 2019 | 211 | 0.130 |
Why?
|
| Complement Factor B | 1 | 2018 | 106 | 0.130 |
Why?
|
| Cells, Cultured | 10 | 2017 | 4151 | 0.130 |
Why?
|
| Prognosis | 5 | 2025 | 4330 | 0.130 |
Why?
|
| Terbutaline | 1 | 2017 | 7 | 0.130 |
Why?
|
| Endothelins | 1 | 2017 | 61 | 0.130 |
Why?
|
| Sex Factors | 3 | 2019 | 2110 | 0.130 |
Why?
|
| Pyridazines | 1 | 2017 | 57 | 0.130 |
Why?
|
| Kidney Glomerulus | 1 | 2018 | 125 | 0.130 |
Why?
|
| Enzyme Stability | 1 | 2017 | 73 | 0.130 |
Why?
|
| Guanosine | 1 | 2017 | 40 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2017 | 178 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2019 | 189 | 0.130 |
Why?
|
| Acute Kidney Injury | 2 | 2018 | 874 | 0.130 |
Why?
|
| Endothelium | 2 | 2014 | 119 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 136 | 0.130 |
Why?
|
| Complement Factor H | 1 | 2018 | 79 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2025 | 962 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2014 | 981 | 0.120 |
Why?
|
| Quality Control | 4 | 2021 | 161 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2017 | 318 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 172 | 0.120 |
Why?
|
| Glutathione | 4 | 2009 | 370 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 265 | 0.120 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 219 | 0.120 |
Why?
|
| Plasma | 2 | 2017 | 223 | 0.120 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2014 | 68 | 0.120 |
Why?
|
| Ischemia | 2 | 2012 | 422 | 0.120 |
Why?
|
| Malathion | 1 | 2016 | 3 | 0.120 |
Why?
|
| Necrosis | 1 | 2017 | 244 | 0.120 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2025 | 1180 | 0.120 |
Why?
|
| Air Pollution | 1 | 2019 | 315 | 0.120 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2016 | 638 | 0.120 |
Why?
|
| Vitamin D | 1 | 2019 | 404 | 0.120 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2015 | 9 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 298 | 0.120 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2007 | 139 | 0.120 |
Why?
|
| Tunica Intima | 2 | 2010 | 78 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 603 | 0.110 |
Why?
|
| Mutation | 2 | 2022 | 4090 | 0.110 |
Why?
|
| Propofol | 1 | 2016 | 85 | 0.110 |
Why?
|
| Imatinib Mesylate | 3 | 2009 | 77 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 293 | 0.110 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 211 | 0.110 |
Why?
|
| Aerosols | 1 | 2016 | 146 | 0.110 |
Why?
|
| Hepatocytes | 2 | 2006 | 224 | 0.110 |
Why?
|
| Gastrectomy | 1 | 2017 | 166 | 0.110 |
Why?
|
| Cerebral Cortex | 2 | 2024 | 474 | 0.110 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 292 | 0.110 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.110 |
Why?
|
| Sex Characteristics | 3 | 2023 | 789 | 0.110 |
Why?
|
| Cholestasis | 3 | 1995 | 214 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2025 | 583 | 0.110 |
Why?
|
| Larva | 1 | 2016 | 240 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 109 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 346 | 0.110 |
Why?
|
| Piperidines | 1 | 2016 | 222 | 0.100 |
Why?
|
| Rabbits | 3 | 2017 | 653 | 0.100 |
Why?
|
| Extinction, Psychological | 1 | 2015 | 92 | 0.100 |
Why?
|
| Benzamides | 3 | 2009 | 226 | 0.100 |
Why?
|
| C-Reactive Protein | 3 | 2022 | 423 | 0.100 |
Why?
|
| Pharmacokinetics | 3 | 2020 | 33 | 0.100 |
Why?
|
| Rats, Inbred WF | 1 | 2014 | 8 | 0.100 |
Why?
|
| HIV Infections | 3 | 2019 | 3195 | 0.100 |
Why?
|
| Apoptosis | 4 | 2017 | 2444 | 0.100 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.100 |
Why?
|
| Carbon Isotopes | 2 | 2024 | 143 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 2017 | 452 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2015 | 183 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2019 | 690 | 0.100 |
Why?
|
| Tidal Volume | 1 | 2014 | 109 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2006 | 199 | 0.100 |
Why?
|
| Least-Squares Analysis | 2 | 2011 | 73 | 0.100 |
Why?
|
| Altitude Sickness | 2 | 2006 | 141 | 0.100 |
Why?
|
| Prostaglandin D2 | 1 | 2013 | 21 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 268 | 0.100 |
Why?
|
| United States | 5 | 2020 | 16126 | 0.100 |
Why?
|
| Drug Resistance, Multiple | 3 | 2002 | 25 | 0.100 |
Why?
|
| Mental Recall | 1 | 2015 | 223 | 0.100 |
Why?
|
| 5'-Nucleotidase | 1 | 2013 | 49 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1969 | 0.100 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2013 | 65 | 0.100 |
Why?
|
| Fatty Acids | 2 | 2014 | 457 | 0.100 |
Why?
|
| Brachial Artery | 3 | 2019 | 208 | 0.100 |
Why?
|
| Neutrophil Infiltration | 1 | 2013 | 107 | 0.100 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2017 | 464 | 0.100 |
Why?
|
| Adenosine Triphosphate | 4 | 2004 | 500 | 0.100 |
Why?
|
| S-Adenosylmethionine | 1 | 2013 | 59 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Cytoprotection | 1 | 2012 | 56 | 0.090 |
Why?
|
| Length of Stay | 1 | 2018 | 1350 | 0.090 |
Why?
|
| Ion Transport | 1 | 2012 | 62 | 0.090 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2013 | 71 | 0.090 |
Why?
|
| Calibration | 4 | 2019 | 152 | 0.090 |
Why?
|
| Models, Theoretical | 3 | 2025 | 560 | 0.090 |
Why?
|
| Hippocampus | 2 | 2026 | 973 | 0.090 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 62 | 0.090 |
Why?
|
| Gluconeogenesis | 1 | 2012 | 81 | 0.090 |
Why?
|
| Iron | 2 | 2010 | 359 | 0.090 |
Why?
|
| Integrins | 1 | 2012 | 90 | 0.090 |
Why?
|
| Aging | 2 | 2015 | 1973 | 0.090 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 19 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 116 | 0.090 |
Why?
|
| Fibronectins | 1 | 2012 | 136 | 0.090 |
Why?
|
| Graft vs Host Disease | 2 | 2000 | 279 | 0.090 |
Why?
|
| Monitoring, Physiologic | 3 | 2012 | 289 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5428 | 0.090 |
Why?
|
| Swine, Miniature | 2 | 2010 | 89 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 611 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2018 | 878 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 668 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 264 | 0.090 |
Why?
|
| Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
|
| Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
|
| Blood Volume | 1 | 2011 | 65 | 0.080 |
Why?
|
| Vagus Nerve | 1 | 2012 | 92 | 0.080 |
Why?
|
| Hot Flashes | 1 | 2012 | 92 | 0.080 |
Why?
|
| Association Learning | 1 | 2012 | 70 | 0.080 |
Why?
|
| Ritonavir | 1 | 2011 | 75 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 165 | 0.080 |
Why?
|
| Morphine Derivatives | 1 | 2011 | 19 | 0.080 |
Why?
|
| Down Syndrome | 1 | 2018 | 525 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2013 | 335 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2015 | 587 | 0.080 |
Why?
|
| Solid Phase Extraction | 1 | 2011 | 25 | 0.080 |
Why?
|
| Lung Injury | 1 | 2014 | 249 | 0.080 |
Why?
|
| Linear Models | 1 | 2013 | 849 | 0.080 |
Why?
|
| Lung | 9 | 2013 | 4116 | 0.080 |
Why?
|
| Disease Progression | 4 | 2022 | 2865 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2011 | 598 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2012 | 1378 | 0.080 |
Why?
|
| Internet | 1 | 2015 | 693 | 0.080 |
Why?
|
| Methylation | 1 | 2011 | 242 | 0.080 |
Why?
|
| Tachyphylaxis | 1 | 2010 | 4 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 285 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 782 | 0.080 |
Why?
|
| Cholinergic Agents | 1 | 2010 | 18 | 0.080 |
Why?
|
| Structure-Activity Relationship | 5 | 2013 | 563 | 0.080 |
Why?
|
| Phenotype | 3 | 2022 | 3170 | 0.080 |
Why?
|
| Verapamil | 2 | 2009 | 37 | 0.080 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2017 | 40 | 0.080 |
Why?
|
| Trigonella | 1 | 2010 | 1 | 0.080 |
Why?
|
| Giant Cells | 1 | 2010 | 21 | 0.080 |
Why?
|
| Twins, Dizygotic | 1 | 2010 | 108 | 0.080 |
Why?
|
| Sensation | 1 | 2010 | 55 | 0.080 |
Why?
|
| Peptide Mapping | 1 | 2010 | 62 | 0.080 |
Why?
|
| Tablets, Enteric-Coated | 2 | 2007 | 5 | 0.080 |
Why?
|
| Twins, Monozygotic | 1 | 2010 | 133 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2013 | 322 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2012 | 403 | 0.080 |
Why?
|
| Micromonosporaceae | 1 | 2009 | 2 | 0.080 |
Why?
|
| Albuminuria | 1 | 2010 | 189 | 0.080 |
Why?
|
| Consumer Product Safety | 1 | 2011 | 80 | 0.080 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 514 | 0.070 |
Why?
|
| Antigens, Plant | 1 | 2010 | 55 | 0.070 |
Why?
|
| Proteinuria | 1 | 2010 | 104 | 0.070 |
Why?
|
| Diclofenac | 1 | 2009 | 14 | 0.070 |
Why?
|
| Conditioning, Classical | 2 | 2024 | 119 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 457 | 0.070 |
Why?
|
| Cell Death | 1 | 2011 | 382 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2012 | 356 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 714 | 0.070 |
Why?
|
| Infusions, Subcutaneous | 1 | 2009 | 23 | 0.070 |
Why?
|
| Risk Factors | 5 | 2025 | 10919 | 0.070 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2012 | 196 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2021 | 172 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 5 | 2000 | 13 | 0.070 |
Why?
|
| Surface Properties | 3 | 2019 | 386 | 0.070 |
Why?
|
| Neoplasms | 2 | 2016 | 2913 | 0.070 |
Why?
|
| Loperamide | 1 | 2009 | 12 | 0.070 |
Why?
|
| Radioimmunoassay | 6 | 1996 | 165 | 0.070 |
Why?
|
| Cross Reactions | 2 | 2007 | 130 | 0.070 |
Why?
|
| Oncogenes | 1 | 2009 | 118 | 0.070 |
Why?
|
| Rats, Inbred Strains | 3 | 2015 | 321 | 0.070 |
Why?
|
| Creatine | 2 | 2006 | 63 | 0.070 |
Why?
|
| Species Specificity | 2 | 2008 | 546 | 0.070 |
Why?
|
| Lymphocyte Activation | 6 | 2003 | 1133 | 0.070 |
Why?
|
| Aorta | 2 | 2003 | 441 | 0.070 |
Why?
|
| Drug Evaluation | 2 | 2000 | 79 | 0.070 |
Why?
|
| Kidney Medulla | 1 | 2008 | 31 | 0.070 |
Why?
|
| Cytokines | 4 | 2025 | 2069 | 0.070 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2008 | 27 | 0.070 |
Why?
|
| Automation | 2 | 2016 | 104 | 0.070 |
Why?
|
| Guinea Pigs | 1 | 2008 | 159 | 0.070 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2006 | 71 | 0.070 |
Why?
|
| Hydroxybutyrates | 2 | 2005 | 15 | 0.070 |
Why?
|
| Taste | 2 | 2024 | 238 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 156 | 0.070 |
Why?
|
| Oxidation-Reduction | 2 | 2009 | 1069 | 0.070 |
Why?
|
| Rats, Inbred F344 | 1 | 2008 | 268 | 0.070 |
Why?
|
| Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 271 | 0.070 |
Why?
|
| Enzymes | 1 | 2008 | 60 | 0.070 |
Why?
|
| Delayed-Action Preparations | 3 | 2017 | 189 | 0.070 |
Why?
|
| Allergens | 1 | 2011 | 386 | 0.070 |
Why?
|
| Macaca mulatta | 1 | 2008 | 186 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2025 | 1115 | 0.070 |
Why?
|
| Receptors, Nicotinic | 1 | 2010 | 327 | 0.070 |
Why?
|
| Switzerland | 1 | 2007 | 46 | 0.070 |
Why?
|
| Drug Combinations | 3 | 2024 | 396 | 0.060 |
Why?
|
| Emulsions | 5 | 2016 | 59 | 0.060 |
Why?
|
| Autoanalysis | 1 | 2007 | 8 | 0.060 |
Why?
|
| Acute Disease | 6 | 2005 | 1036 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2011 | 140 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2025 | 356 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2019 | 2181 | 0.060 |
Why?
|
| NAD | 2 | 2004 | 79 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2013 | 117 | 0.060 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2007 | 62 | 0.060 |
Why?
|
| Serum Albumin | 3 | 2019 | 147 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2013 | 517 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 298 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2007 | 94 | 0.060 |
Why?
|
| Nitric Oxide | 3 | 2017 | 892 | 0.060 |
Why?
|
| Caco-2 Cells | 3 | 2003 | 79 | 0.060 |
Why?
|
| Fetus | 2 | 2021 | 804 | 0.060 |
Why?
|
| Organ Preservation Solutions | 1 | 2006 | 46 | 0.060 |
Why?
|
| Lactic Acid | 4 | 2009 | 295 | 0.060 |
Why?
|
| Immune Tolerance | 3 | 2017 | 385 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2012 | 1134 | 0.060 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 203 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 574 | 0.060 |
Why?
|
| Body Weight | 5 | 2001 | 972 | 0.060 |
Why?
|
| Liver Diseases | 2 | 2024 | 305 | 0.060 |
Why?
|
| Glycine Dehydrogenase (Decarboxylating) | 1 | 2026 | 13 | 0.060 |
Why?
|
| Macaca | 1 | 2006 | 66 | 0.060 |
Why?
|
| Food-Drug Interactions | 1 | 2005 | 11 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2005 | 39 | 0.060 |
Why?
|
| Technology, Pharmaceutical | 1 | 2005 | 30 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 435 | 0.060 |
Why?
|
| Triiodothyronine | 1 | 2026 | 55 | 0.060 |
Why?
|
| Lactates | 1 | 2005 | 82 | 0.060 |
Why?
|
| Methylamines | 1 | 2005 | 39 | 0.060 |
Why?
|
| Healthy Volunteers | 1 | 2026 | 219 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 381 | 0.060 |
Why?
|
| Phosphorylation | 5 | 2012 | 1708 | 0.060 |
Why?
|
| Thyroid Hormones | 1 | 2026 | 69 | 0.060 |
Why?
|
| Ships | 1 | 1985 | 4 | 0.060 |
Why?
|
| Exercise | 1 | 2017 | 2205 | 0.060 |
Why?
|
| Ultrasonics | 2 | 2002 | 50 | 0.060 |
Why?
|
| Organ Preservation | 1 | 2006 | 125 | 0.060 |
Why?
|
| Iliac Artery | 2 | 2017 | 55 | 0.060 |
Why?
|
| Organ Size | 3 | 2015 | 461 | 0.060 |
Why?
|
| Posture | 1 | 2006 | 197 | 0.060 |
Why?
|
| Hair | 1 | 2025 | 84 | 0.060 |
Why?
|
| Streptozocin | 1 | 2005 | 22 | 0.050 |
Why?
|
| Deuterium | 1 | 2005 | 102 | 0.050 |
Why?
|
| Triglycerides | 3 | 2011 | 520 | 0.050 |
Why?
|
| CD55 Antigens | 1 | 2005 | 29 | 0.050 |
Why?
|
| Paraplegia | 1 | 1985 | 60 | 0.050 |
Why?
|
| Hot Temperature | 2 | 2012 | 396 | 0.050 |
Why?
|
| Complement Inactivator Proteins | 1 | 2005 | 39 | 0.050 |
Why?
|
| Echocardiography | 2 | 2024 | 648 | 0.050 |
Why?
|
| Colorado | 5 | 2021 | 4556 | 0.050 |
Why?
|
| Asthma | 1 | 2016 | 1797 | 0.050 |
Why?
|
| Troleandomycin | 3 | 1999 | 3 | 0.050 |
Why?
|
| Drug Design | 1 | 2005 | 175 | 0.050 |
Why?
|
| Steroids | 2 | 2005 | 160 | 0.050 |
Why?
|
| Vasodilation | 2 | 2018 | 521 | 0.050 |
Why?
|
| Saccharin | 1 | 2024 | 9 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 74 | 0.050 |
Why?
|
| Warfarin | 1 | 2006 | 179 | 0.050 |
Why?
|
| Pulmonary Artery | 2 | 2007 | 1129 | 0.050 |
Why?
|
| Calcineurin | 2 | 2004 | 105 | 0.050 |
Why?
|
| Propylene Glycols | 1 | 2024 | 28 | 0.050 |
Why?
|
| Stress, Psychological | 2 | 2025 | 1151 | 0.050 |
Why?
|
| Receptors, Complement | 1 | 2005 | 123 | 0.050 |
Why?
|
| Cholesterol, HDL | 2 | 2013 | 201 | 0.050 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2004 | 4 | 0.050 |
Why?
|
| Insulin Infusion Systems | 1 | 2009 | 480 | 0.050 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
|
| Isotopes | 1 | 2024 | 33 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1101 | 0.050 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2004 | 40 | 0.050 |
Why?
|
| DNA | 2 | 2009 | 1437 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 883 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 1997 | 1300 | 0.050 |
Why?
|
| Saliva | 1 | 2025 | 249 | 0.050 |
Why?
|
| Glycerol | 1 | 2024 | 90 | 0.050 |
Why?
|
| Antitubercular Agents | 1 | 2005 | 208 | 0.050 |
Why?
|
| Plant Leaves | 1 | 2024 | 131 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2025 | 328 | 0.050 |
Why?
|
| Protein Binding | 3 | 2018 | 2240 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 887 | 0.050 |
Why?
|
| Obesity | 1 | 2017 | 3118 | 0.050 |
Why?
|
| Midazolam | 1 | 2003 | 73 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 202 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2004 | 209 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2025 | 270 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2026 | 269 | 0.050 |
Why?
|
| Altitude | 3 | 2017 | 463 | 0.050 |
Why?
|
| Complement Membrane Attack Complex | 2 | 2018 | 38 | 0.050 |
Why?
|
| NADP | 2 | 1994 | 52 | 0.050 |
Why?
|
| Pancreas Transplantation | 1 | 2003 | 71 | 0.050 |
Why?
|
| Insulin | 3 | 2009 | 2516 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 172 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 6085 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 968 | 0.050 |
Why?
|
| Leukocytes | 1 | 2024 | 296 | 0.050 |
Why?
|
| Ketoconazole | 2 | 1999 | 3 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2000 | 112 | 0.050 |
Why?
|
| Sports | 1 | 1985 | 212 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 3 | 2010 | 347 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2025 | 466 | 0.050 |
Why?
|
| Myelin Sheath | 1 | 2024 | 166 | 0.050 |
Why?
|
| Isoflurane | 1 | 2002 | 41 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 552 | 0.040 |
Why?
|
| Oral Mucosal Absorption | 1 | 2021 | 1 | 0.040 |
Why?
|
| Hepatobiliary Elimination | 1 | 2021 | 1 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2021 | 12 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2024 | 190 | 0.040 |
Why?
|
| Reperfusion | 1 | 2002 | 54 | 0.040 |
Why?
|
| Wine | 1 | 2001 | 13 | 0.040 |
Why?
|
| Cognition | 2 | 2023 | 1271 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2021 | 27 | 0.040 |
Why?
|
| Plant Preparations | 1 | 2002 | 37 | 0.040 |
Why?
|
| Oxaloacetic Acid | 1 | 2001 | 4 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 2001 | 55 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 5925 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2022 | 302 | 0.040 |
Why?
|
| Biological Transport | 2 | 2003 | 424 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2006 | 375 | 0.040 |
Why?
|
| Cell Survival | 3 | 2012 | 1104 | 0.040 |
Why?
|
| Hyperthermia, Induced | 1 | 2002 | 120 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2002 | 78 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2021 | 119 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2024 | 520 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 2001 | 88 | 0.040 |
Why?
|
| Motivation | 1 | 2026 | 602 | 0.040 |
Why?
|
| Glomerular Mesangium | 2 | 1991 | 21 | 0.040 |
Why?
|
| Microchemistry | 3 | 2000 | 19 | 0.040 |
Why?
|
| Tryptophan | 1 | 2022 | 182 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 89 | 0.040 |
Why?
|
| Self Report | 1 | 2025 | 876 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2012 | 202 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 1723 | 0.040 |
Why?
|
| Haplotypes | 2 | 2013 | 500 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2024 | 447 | 0.040 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2013 | 362 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2001 | 499 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2022 | 238 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2123 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2000 | 52 | 0.040 |
Why?
|
| 2,4-Dinitrophenol | 1 | 2000 | 9 | 0.040 |
Why?
|
| LLC-PK1 Cells | 1 | 2000 | 18 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2000 | 273 | 0.040 |
Why?
|
| Antimetabolites | 1 | 2000 | 21 | 0.040 |
Why?
|
| Reward | 1 | 2022 | 248 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2020 | 148 | 0.040 |
Why?
|
| Logistic Models | 2 | 2022 | 2139 | 0.040 |
Why?
|
| 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2004 | 517 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2002 | 387 | 0.040 |
Why?
|
| Child Development | 1 | 2024 | 483 | 0.040 |
Why?
|
| Heart | 1 | 2003 | 626 | 0.040 |
Why?
|
| Transplantation, Heterotopic | 1 | 1999 | 16 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2018 | 3752 | 0.040 |
Why?
|
| Rats, Inbred BN | 4 | 2000 | 56 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.040 |
Why?
|
| Eicosanoids | 1 | 2019 | 58 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 196 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2009 | 2344 | 0.040 |
Why?
|
| K562 Cells | 2 | 2009 | 92 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2020 | 164 | 0.040 |
Why?
|
| Citrus | 1 | 1999 | 12 | 0.040 |
Why?
|
| Diet | 2 | 2019 | 1278 | 0.040 |
Why?
|
| Epithelium | 1 | 2000 | 311 | 0.040 |
Why?
|
| Individuality | 1 | 2000 | 149 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 199 | 0.040 |
Why?
|
| Maternal Age | 1 | 2019 | 128 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 3 | 2001 | 1505 | 0.040 |
Why?
|
| Beverages | 1 | 1999 | 68 | 0.040 |
Why?
|
| Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
|
| Hypertension | 1 | 2007 | 1276 | 0.030 |
Why?
|
| Complement C5a | 1 | 2018 | 54 | 0.030 |
Why?
|
| Amides | 1 | 1999 | 101 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2001 | 558 | 0.030 |
Why?
|
| Analgesics | 1 | 2020 | 231 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2018 | 28 | 0.030 |
Why?
|
| Food Hypersensitivity | 2 | 2011 | 164 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2018 | 36 | 0.030 |
Why?
|
| Europe | 1 | 1999 | 421 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2014 | 1165 | 0.030 |
Why?
|
| F2-Isoprostanes | 2 | 2009 | 21 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2018 | 65 | 0.030 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2018 | 25 | 0.030 |
Why?
|
| Solutions | 2 | 2016 | 159 | 0.030 |
Why?
|
| Ions | 1 | 2018 | 66 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 195 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2018 | 62 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
|
| Nifedipine | 1 | 1997 | 27 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 1998 | 120 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 421 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 1998 | 95 | 0.030 |
Why?
|
| Nitriles | 1 | 1999 | 211 | 0.030 |
Why?
|
| Bioreactors | 1 | 2018 | 50 | 0.030 |
Why?
|
| Urea | 1 | 2018 | 85 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 442 | 0.030 |
Why?
|
| Bronchi | 1 | 1999 | 263 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2011 | 197 | 0.030 |
Why?
|
| Intestines | 1 | 2000 | 354 | 0.030 |
Why?
|
| Veterans Health | 1 | 2019 | 190 | 0.030 |
Why?
|
| Weight Gain | 1 | 2001 | 561 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 2131 | 0.030 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 68 | 0.030 |
Why?
|
| Archaeal Proteins | 1 | 2017 | 50 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2019 | 347 | 0.030 |
Why?
|
| Cholesterol, VLDL | 1 | 1996 | 5 | 0.030 |
Why?
|
| Schizophrenic Psychology | 1 | 2017 | 99 | 0.030 |
Why?
|
| Anxiety | 1 | 2024 | 1122 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1999 | 286 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2008 | 156 | 0.030 |
Why?
|
| Temperature | 1 | 2000 | 633 | 0.030 |
Why?
|
| Malates | 1 | 2016 | 8 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 2883 | 0.030 |
Why?
|
| Postmenopause | 1 | 2019 | 394 | 0.030 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 63 | 0.030 |
Why?
|
| Hydrolysis | 2 | 2013 | 197 | 0.030 |
Why?
|
| Women's Health | 1 | 2019 | 316 | 0.030 |
Why?
|
| Catheterization | 1 | 2017 | 184 | 0.030 |
Why?
|
| Stroke | 1 | 2006 | 1271 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 1996 | 30 | 0.030 |
Why?
|
| Cell Count | 2 | 2013 | 319 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 210 | 0.030 |
Why?
|
| Betaine | 1 | 2016 | 67 | 0.030 |
Why?
|
| Anterior Chamber | 1 | 1996 | 26 | 0.030 |
Why?
|
| Materials Testing | 1 | 2018 | 345 | 0.030 |
Why?
|
| Anesthesia, Intravenous | 1 | 2016 | 24 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2019 | 353 | 0.030 |
Why?
|
| Leukotriene B4 | 1 | 2016 | 36 | 0.030 |
Why?
|
| Bromocriptine | 1 | 1996 | 31 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 93 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 2602 | 0.030 |
Why?
|
| Nicotinic Agonists | 1 | 2017 | 135 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 1996 | 54 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 735 | 0.030 |
Why?
|
| Duodenum | 1 | 1996 | 77 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2024 | 2447 | 0.030 |
Why?
|
| Artificial Organs | 1 | 1995 | 2 | 0.030 |
Why?
|
| Syringes | 1 | 2016 | 49 | 0.030 |
Why?
|
| Epitopes | 1 | 2018 | 473 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2020 | 620 | 0.030 |
Why?
|
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 5 | 0.030 |
Why?
|
| Linoleic Acids | 1 | 2015 | 6 | 0.030 |
Why?
|
| Health Policy | 1 | 1999 | 400 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 1957 | 0.030 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.030 |
Why?
|
| Incidence | 2 | 2018 | 2934 | 0.030 |
Why?
|
| Neuroglia | 1 | 1996 | 174 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2019 | 693 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 396 | 0.030 |
Why?
|
| Estradiol | 1 | 2019 | 515 | 0.030 |
Why?
|
| Citric Acid Cycle | 2 | 2010 | 58 | 0.030 |
Why?
|
| Asialoglycoproteins | 1 | 1995 | 2 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 707 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 2018 | 314 | 0.030 |
Why?
|
| Rhodamines | 1 | 1995 | 19 | 0.030 |
Why?
|
| Safety | 1 | 2017 | 358 | 0.030 |
Why?
|
| Heat-Shock Proteins | 2 | 2007 | 139 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1995 | 42 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2017 | 242 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 461 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 1996 | 360 | 0.030 |
Why?
|
| Oxides | 1 | 1995 | 47 | 0.030 |
Why?
|
| Lipoproteins, VLDL | 1 | 2014 | 21 | 0.030 |
Why?
|
| Uteroglobin | 1 | 2014 | 31 | 0.030 |
Why?
|
| Extracellular Matrix | 2 | 1996 | 563 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 441 | 0.030 |
Why?
|
| Particle Size | 1 | 2016 | 381 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 396 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 571 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2010 | 562 | 0.030 |
Why?
|
| Ferric Compounds | 1 | 1995 | 54 | 0.030 |
Why?
|
| Nitrites | 1 | 2014 | 88 | 0.030 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.030 |
Why?
|
| Kidney Function Tests | 3 | 2006 | 156 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2015 | 440 | 0.030 |
Why?
|
| Dasatinib | 1 | 2014 | 58 | 0.030 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
|
| Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
|
| Nitrates | 1 | 2014 | 96 | 0.030 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2013 | 20 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1038 | 0.030 |
Why?
|
| Insufflation | 1 | 2013 | 14 | 0.030 |
Why?
|
| Nevirapine | 1 | 2013 | 18 | 0.020 |
Why?
|
| Benzoxazines | 1 | 2013 | 31 | 0.020 |
Why?
|
| Thiazoles | 1 | 2014 | 142 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 1999 | 81 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2013 | 84 | 0.020 |
Why?
|
| Phospholipases | 1 | 2013 | 14 | 0.020 |
Why?
|
| Alkynes | 1 | 2013 | 67 | 0.020 |
Why?
|
| Mannitol | 2 | 2006 | 40 | 0.020 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2013 | 23 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2020 | 509 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2013 | 1599 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2017 | 544 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 2399 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2012 | 53 | 0.020 |
Why?
|
| Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.020 |
Why?
|
| Mothers | 1 | 2019 | 766 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 65 | 0.020 |
Why?
|
| Smoking | 1 | 2020 | 1477 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1995 | 372 | 0.020 |
Why?
|
| Body Composition | 1 | 2016 | 693 | 0.020 |
Why?
|
| Complement C3 | 1 | 2013 | 187 | 0.020 |
Why?
|
| Leucovorin | 1 | 2012 | 98 | 0.020 |
Why?
|
| Heart Rate | 2 | 2009 | 856 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2012 | 75 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2017 | 481 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 88 | 0.020 |
Why?
|
| Vascular System Injuries | 1 | 2013 | 81 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 145 | 0.020 |
Why?
|
| Nucleoside Transport Proteins | 1 | 2012 | 8 | 0.020 |
Why?
|
| No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
|
| Asialoglycoprotein Receptor | 2 | 2006 | 6 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 211 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2012 | 30 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 194 | 0.020 |
Why?
|
| Heart Ventricles | 2 | 2007 | 756 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 784 | 0.020 |
Why?
|
| Methylcholanthrene | 1 | 1991 | 21 | 0.020 |
Why?
|
| Phenobarbital | 1 | 1991 | 21 | 0.020 |
Why?
|
| Proteolysis | 1 | 2012 | 172 | 0.020 |
Why?
|
| Fear | 1 | 2015 | 368 | 0.020 |
Why?
|
| Chimerism | 1 | 2012 | 35 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 174 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 3937 | 0.020 |
Why?
|
| Darunavir | 1 | 2011 | 20 | 0.020 |
Why?
|
| Dealkylation | 1 | 1991 | 3 | 0.020 |
Why?
|
| Actins | 2 | 2007 | 426 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2017 | 1118 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2013 | 190 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2013 | 205 | 0.020 |
Why?
|
| Glucuronates | 1 | 1991 | 5 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2012 | 73 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 279 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 1991 | 54 | 0.020 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 7 | 0.020 |
Why?
|
| Contrast Media | 1 | 1995 | 497 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2012 | 231 | 0.020 |
Why?
|
| Overweight | 1 | 2016 | 614 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 1991 | 29 | 0.020 |
Why?
|
| Centrifugation | 1 | 1991 | 28 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 3 | 1996 | 200 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2016 | 578 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2012 | 192 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 371 | 0.020 |
Why?
|
| Food Analysis | 1 | 2011 | 22 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 2601 | 0.020 |
Why?
|
| Alfentanil | 1 | 2010 | 7 | 0.020 |
Why?
|
| Aldehydes | 1 | 1991 | 140 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 118 | 0.020 |
Why?
|
| Pain Perception | 1 | 2010 | 24 | 0.020 |
Why?
|
| Cell Division | 3 | 2001 | 757 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 638 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2010 | 182 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2933 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2010 | 54 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 858 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1150 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 938 | 0.020 |
Why?
|
| Blood | 2 | 2000 | 107 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 896 | 0.020 |
Why?
|
| Spinacia oleracea | 1 | 2009 | 10 | 0.020 |
Why?
|
| Granuloma | 1 | 2010 | 97 | 0.020 |
Why?
|
| Proteins | 1 | 1995 | 1023 | 0.020 |
Why?
|
| Fibrin | 1 | 2010 | 84 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 177 | 0.020 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 376 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 160 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2011 | 203 | 0.020 |
Why?
|
| Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2009 | 85 | 0.020 |
Why?
|
| Serbia | 1 | 2008 | 7 | 0.020 |
Why?
|
| Insulin Lispro | 1 | 2009 | 42 | 0.020 |
Why?
|
| Succinic Acid | 1 | 2009 | 46 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 615 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2009 | 51 | 0.020 |
Why?
|
| Free Radicals | 1 | 2009 | 105 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 185 | 0.020 |
Why?
|
| Bronchoscopy | 2 | 2000 | 227 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 383 | 0.020 |
Why?
|
| Urinalysis | 1 | 2009 | 83 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 6033 | 0.020 |
Why?
|
| Osmotic Pressure | 1 | 2008 | 41 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2008 | 43 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1988 | 312 | 0.020 |
Why?
|
| Monocrotaline | 1 | 2007 | 31 | 0.020 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2007 | 13 | 0.020 |
Why?
|
| Naloxone | 1 | 2009 | 132 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 1998 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 279 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 848 | 0.020 |
Why?
|
| Wound Healing | 1 | 2010 | 355 | 0.020 |
Why?
|
| HIV-1 | 1 | 2013 | 908 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2007 | 52 | 0.020 |
Why?
|
| Technetium | 1 | 2006 | 10 | 0.020 |
Why?
|
| Animals, Outbred Strains | 1 | 2006 | 6 | 0.020 |
Why?
|
| Antibodies, Heterophile | 1 | 2006 | 12 | 0.020 |
Why?
|
| Systole | 1 | 2007 | 181 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1988 | 283 | 0.020 |
Why?
|
| Radiography | 2 | 2000 | 853 | 0.020 |
Why?
|
| Cell Size | 2 | 1997 | 93 | 0.020 |
Why?
|
| Dosage Forms | 2 | 1996 | 11 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2006 | 39 | 0.020 |
Why?
|
| Serum Albumin, Human | 1 | 2006 | 7 | 0.020 |
Why?
|
| Raffinose | 1 | 2006 | 29 | 0.020 |
Why?
|
| Lysine | 1 | 2009 | 305 | 0.020 |
Why?
|
| Procaine | 1 | 2006 | 10 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1261 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 116 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2006 | 40 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 153 | 0.020 |
Why?
|
| Insulin, Regular, Human | 1 | 2006 | 47 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 120 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 778 | 0.020 |
Why?
|
| Allopurinol | 1 | 2006 | 70 | 0.010 |
Why?
|
| Portal System | 1 | 2006 | 12 | 0.010 |
Why?
|
| Insulin, Long-Acting | 1 | 2006 | 65 | 0.010 |
Why?
|
| Random Allocation | 1 | 2007 | 365 | 0.010 |
Why?
|
| Biopsy | 2 | 2000 | 1082 | 0.010 |
Why?
|
| Cold Ischemia | 1 | 2006 | 40 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 979 | 0.010 |
Why?
|
| Contraindications | 1 | 2006 | 90 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2006 | 247 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2007 | 293 | 0.010 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2006 | 78 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2009 | 563 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2005 | 196 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 2968 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2009 | 380 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2006 | 330 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2009 | 835 | 0.010 |
Why?
|
| Drug Compounding | 1 | 2005 | 107 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1996 | 414 | 0.010 |
Why?
|
| Travel | 1 | 2006 | 136 | 0.010 |
Why?
|
| Nanostructures | 1 | 2005 | 105 | 0.010 |
Why?
|
| Spleen | 1 | 2006 | 508 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 1478 | 0.010 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 360 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1043 | 0.010 |
Why?
|
| Motor Skills | 1 | 1985 | 104 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 2191 | 0.010 |
Why?
|
| Polymers | 1 | 2008 | 485 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 247 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2006 | 274 | 0.010 |
Why?
|
| Absorption | 1 | 2003 | 60 | 0.010 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2003 | 31 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2007 | 655 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 2003 | 83 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2004 | 94 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 2875 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2007 | 544 | 0.010 |
Why?
|
| Cardiac Output | 1 | 2003 | 179 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 2003 | 134 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2006 | 1083 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 2 | 1994 | 42 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2002 | 30 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 176 | 0.010 |
Why?
|
| Alanine | 1 | 2003 | 169 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 196 | 0.010 |
Why?
|
| Alkaline Phosphatase | 2 | 1994 | 144 | 0.010 |
Why?
|
| Rhodamine 123 | 1 | 2001 | 8 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1995 | 3916 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2001 | 27 | 0.010 |
Why?
|
| Microcirculation | 1 | 2002 | 142 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 2001 | 29 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 927 | 0.010 |
Why?
|
| Calorimetry | 1 | 2001 | 69 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 1812 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 2001 | 141 | 0.010 |
Why?
|
| Quantum Theory | 1 | 2001 | 86 | 0.010 |
Why?
|
| Cell Membrane | 2 | 1995 | 709 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2002 | 246 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2000 | 89 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 1782 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 946 | 0.010 |
Why?
|
| Autopsy | 1 | 2000 | 94 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 1991 | 49 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2006 | 558 | 0.010 |
Why?
|
| Diuretics, Osmotic | 1 | 1999 | 2 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 2006 | 847 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2001 | 403 | 0.010 |
Why?
|
| Crotonates | 1 | 1999 | 7 | 0.010 |
Why?
|
| Toluidines | 1 | 1999 | 10 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 2805 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 306 | 0.010 |
Why?
|
| Thermodynamics | 1 | 2001 | 419 | 0.010 |
Why?
|
| Capsules | 2 | 1990 | 42 | 0.010 |
Why?
|
| Vinblastine | 1 | 1999 | 75 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2003 | 788 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2000 | 351 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1999 | 106 | 0.010 |
Why?
|
| Isoxazoles | 1 | 1999 | 56 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 740 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 428 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 528 | 0.010 |
Why?
|
| Aniline Compounds | 1 | 1999 | 120 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 1999 | 172 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 1311 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2000 | 450 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 666 | 0.010 |
Why?
|
| Cytosol | 1 | 1997 | 213 | 0.010 |
Why?
|
| Spectrometry, Mass, Secondary Ion | 1 | 1996 | 2 | 0.010 |
Why?
|
| Acetic Anhydrides | 1 | 1996 | 3 | 0.010 |
Why?
|
| Azathioprine | 1 | 1996 | 44 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2001 | 1003 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2000 | 420 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1482 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1996 | 82 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1996 | 155 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 1996 | 82 | 0.010 |
Why?
|
| Acetonitriles | 1 | 1995 | 12 | 0.010 |
Why?
|
| Bile Canaliculi | 1 | 1995 | 4 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 1736 | 0.010 |
Why?
|
| Albumins | 1 | 1996 | 119 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1995 | 295 | 0.010 |
Why?
|
| Fetuins | 1 | 1995 | 3 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 1996 | 152 | 0.010 |
Why?
|
| Cornea | 1 | 1996 | 154 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1995 | 37 | 0.010 |
Why?
|
| Ferrosoferric Oxide | 1 | 1995 | 25 | 0.010 |
Why?
|
| Cataract Extraction | 1 | 1996 | 120 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1996 | 206 | 0.010 |
Why?
|
| Skin | 1 | 1999 | 754 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 164 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1996 | 330 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1994 | 179 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1995 | 451 | 0.010 |
Why?
|
| Vinca Alkaloids | 1 | 1993 | 6 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1993 | 16 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1993 | 25 | 0.010 |
Why?
|
| Succinimides | 1 | 1993 | 21 | 0.010 |
Why?
|
| Collagen | 1 | 1996 | 457 | 0.010 |
Why?
|
| Bile Acids and Salts | 1 | 1994 | 163 | 0.010 |
Why?
|
| Cricetulus | 1 | 1993 | 118 | 0.010 |
Why?
|
| CHO Cells | 1 | 1993 | 169 | 0.010 |
Why?
|
| Algorithms | 1 | 2001 | 1851 | 0.010 |
Why?
|
| Cricetinae | 1 | 1993 | 305 | 0.010 |
Why?
|
| Norpregnenes | 1 | 1992 | 4 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1993 | 145 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 67 | 0.010 |
Why?
|
| Water | 1 | 1995 | 448 | 0.010 |
Why?
|
| Glutamate Dehydrogenase | 1 | 1991 | 4 | 0.010 |
Why?
|
| Cholinesterases | 1 | 1991 | 9 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1991 | 168 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1991 | 85 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1991 | 151 | 0.000 |
Why?
|
| Oils | 1 | 1990 | 22 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1993 | 729 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1987 | 49 | 0.000 |
Why?
|
| Gelatin | 1 | 1988 | 56 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1994 | 777 | 0.000 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 104 | 0.000 |
Why?
|
| CD3 Complex | 1 | 1987 | 112 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1987 | 673 | 0.000 |
Why?
|